Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1627 1691
This examiner grants 66% of resolved cases
Elena Vladimirovna Vishnyakova serves as an examiner in Art Unit 1627 within Tech Center 1600. The examiner has handled 38 resolved cases. The data indicates an allowance rate of 65.8% for these applications. This 65.8% rate serves as a key metric for practitioners to assess the likelihood of a positive outcome during the examination process. The 38 resolved cases provide a data set for understanding the examiner's historical tendencies.
The median days to allowance for cases assigned to this examiner is 1108. This 1108-day timeline offers a realistic expectation for the duration of the prosecution cycle from filing to grant. A significant data point is the 51.3% interview lift. This 51.3% lift indicates that the probability of allowance increases substantially when an interview is conducted. Practitioners should consider the 51.3% lift as a primary reason to engage in direct communication with the examiner. The 1108-day median pendency and the 65.8% allowance rate are important factors for strategic planning. Using the 51.3% interview lift can help navigate the prosecution process much more effectively than through written responses alone.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277524 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | Non-Final OA | LG CHEM, LTD. |
| 18455578 | IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF | Final Rejection | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED |
| 18717529 | PHARMACEUTICAL COMBINATION COMPRISING ABEMACICLIB AND A PI3K AND/OR A MTOR INHIBITOR FOR THE TREATMENT OF MANTLE CELL LYMPHOMA | Non-Final OA | Board of Regents, The University of Texas System |
| 18002710 | PanK Modulators and Methods Using Same | Non-Final OA | YALE UNIVERSITY |
| 18834679 | SUNFLOWER OLEOSOME CONCENTRATE AND PROCESS FOR PREPARING IT | Non-Final OA | CARGILL, INCORPORATED |
| 18569148 | PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF | Non-Final OA | INSTITUTE OF MATERIA MEDICA ,CHINESE ACADEMY OF MEDICAL SCIENCES |
| 18037515 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | Non-Final OA | Bexson Biomedical, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy